Table 3.
Blood loss, blood product use and procoagulant interventions among the control and case group patients.
| EBL (mL) | EBL (>500) | RBC1 | FFP | Cryo | PLT | Any BLP | PCC | TXA | |
|---|---|---|---|---|---|---|---|---|---|
| All controls (n=65) | 400 (300–500) | 10 (15.4) | 10 (15.4) | 11 (16.9) | 2 (3.1) | 7 (10.8) | 23 (35.4) | 1 (1.5) | 25 (38.5) |
| Control-N (n=39) | 400 (300–500) | 5 (12.8) | 5 (12.8) | 4 (10.3) | 0 (0) | 0 (0)* | 6 (15.4)* | 0 (0) | 15 (38.5) |
| Control-CP (n=26) | 400 (300–500) | 5 (19.2) | 5 (19.2) | 7 (26.9) | 2 (7.7) | 7 (26.9)* | 17 (65.4)* | 1 (3.8) | 10 (38.5) |
| All cases (n=69) | 400 (300–500) | 15 (21.7) | 13 (18.8) | 9 (13) | 7 (10.1) | 8 (11.6) | 24 (34.8) | 61 (1.4) | 25 (36.2) |
| Case-N (n=35) | 400 (300–500) | 6 (17.1) | 5 (14.3) | 1 (2.9)* | 1 (2.9)* | 0 (0)* | 4 (11.4)* | 0 (0) | 7 (20.0)* |
| Case-CP (n=34) | 400 (300–600) | 9 (26.5) | 8 (23.5) | 8 (23.5)* | 6 (17.6)* | 8 (23.5)* | 20 (58.8)* | 1 (2.9) | 18 (52.9)* |
1
RBC’s were transfused if hemoglobin was <90 g/L.
*
Statistically significant differences between normal versus coagulopathic patient subgroups within controls and cases, P<0.05.
Continuous variables are reported as median (interquartile range). Categorical variables are reported in terms of frequency (percentage). N – normal; CP – coagulopathic; EBL – estimated blood loss; RBC – red blood cells; FFP – fresh frozen plasma; Cryo – cryoprecipitate; PLT – platelets; PCC – prothrombin complex concentrate, TXA – tranexamic acid; BLP – blood product.